Vascepa Risk for Atrial Fibrillation
Vascepa (icosapent ethyl) at the approved dose of 4 grams daily increases the risk of atrial fibrillation by approximately 35%, with an absolute risk increase of 1.4% (5.3% vs 3.9% placebo), and this risk nearly doubles in patients with a prior history of atrial fibrillation.
Quantified Risk from Pivotal Trial
The REDUCE-IT trial, which led to FDA approval, demonstrated clear atrial fibrillation risk 1, 2:
- Overall atrial fibrillation rate: 5.3% with icosapent ethyl vs 3.9% with placebo (P = 0.003)
- Hospitalization for atrial fibrillation: 3.1% vs 2.1% (P = 0.004)
- Absolute risk increase: 1.4% for any atrial fibrillation, 1.0% for hospitalized atrial fibrillation
Risk Stratification by Patient History
The atrial fibrillation risk is not uniform across all patients 3:
- Patients WITH prior atrial fibrillation: 12.5% developed in-study atrial fibrillation on icosapent ethyl vs 6.3% on placebo (hazard ratio 1.96, P = 0.007)
- Patients WITHOUT prior atrial fibrillation: 2.2% vs 1.6% (P = 0.09, not statistically significant)
This represents a near-doubling of risk in patients with prior atrial fibrillation history, making this the highest-risk subgroup.
FDA-Mandated Warning
The FDA label explicitly includes atrial fibrillation as a boxed warning 2:
"VASCEPA was associated with an increased risk of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter."
Clinical Context: Risk vs Benefit
Despite the atrial fibrillation risk, cardiovascular benefit was maintained even in patients who developed atrial fibrillation 3:
- Patients with prior atrial fibrillation still achieved similar relative risk reductions in cardiovascular death, myocardial infarction, and stroke with icosapent ethyl
- The 25% reduction in major adverse cardiovascular events (17.2% vs 22.0%, P < 0.001) 1, 4 substantially outweighs the atrial fibrillation risk in appropriate patients
Real-World Safety Data
Post-marketing surveillance suggests the real-world incidence may be lower than trial data 5, 6:
- MarketScan database analysis showed real-world atrial fibrillation rates were one-third to one-fifth of REDUCE-IT trial rates
- FAERS database analysis confirmed increased atrial fibrillation risk but found icosapent ethyl generally well-tolerated 6
Mechanism
The mechanism for increased atrial fibrillation remains unclear but may relate to omega-3 fatty acids' effects on cardiac electrophysiology 7:
- Omega-3 fatty acids reduce sodium current and shorten atrial action potential duration
- These effects may suppress some arrhythmias while favoring reentrant mechanisms that trigger atrial fibrillation
Clinical Algorithm for Use
Screen for atrial fibrillation history before prescribing:
- No prior atrial fibrillation: Proceed with icosapent ethyl if indicated; absolute risk increase is minimal (~0.6%)
- Prior atrial fibrillation: Use with heightened caution; counsel patient about doubled risk (absolute increase ~6%)
- Active/uncontrolled atrial fibrillation: Consider alternative therapies or ensure optimal rate/rhythm control before initiating
Monitor during treatment:
- Educate patients about atrial fibrillation symptoms (palpitations, dyspnea, fatigue)
- Consider baseline and periodic ECGs in high-risk patients
- Maintain low threshold for evaluation if symptoms develop
Common Pitfall
Do not withhold icosapent ethyl solely based on atrial fibrillation risk in patients with established cardiovascular disease and elevated triglycerides. The mortality and morbidity benefit from preventing myocardial infarction, stroke, and cardiovascular death (26.5% relative risk reduction for hard endpoints 1) substantially exceeds the atrial fibrillation risk, even in patients with prior atrial fibrillation 3. The key is informed consent and appropriate monitoring, not avoidance.